Skip to content
Open in App
Cytokinetics logo

Cytokinetics

web2

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, an...

Symbol · 1CYTK
Company profile

About

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: 1CYTK
ExchangeMilanPrimary symbol: 1CYTK
Expert coverage

1 expert evaluated Cytokinetics.

Orbitrum research

Experts evaluating Cytokinetics

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment